Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is why shakerzzzzzzzzz recieved 20mil shares for pumping.
They weren't going to be worth much at .0001
Are you? if it goes to no bid?
I think its actually Pags
So you agree it doesn't look as atractive as it did 48 hours ago
lol, that was 48 hours ago
according to this you do:
Posted by: soupoftheday Date: Monday, March 23, 2009 12:28:38 PM
In reply to: Derekz who wrote msg# 17333 Post # of 17676
Realistic? 25 cents minimum!!!
So if it gets back to reverse split break even, which i'm sure you believe it will and them some.
at .03 pps =shakerzzzzzzzzzz 20mill shares
He is giving shakerzzzzzzzzz $600,000.00 to raise awareness?
Can somebody explain how this stock is not a scam based on this.
Pags needs $125,000 to pay off debt.
So he dilutes
He telling people this is going to .20 cents
Why in hell would he give shakerzzzzzzzzzzzzz 20 mil shares to flap his gums.
20mil shares sold at .01cent is $200,000.00
So if he truly has something that can increase the pps like he claims, he's giving shakerzzzzzzzzzz 200,000.00 to help him generate 125,000.00.
How does this make sense?
Why not just put out the holy grail of pr's (the golf channel) and dilute into it and it would seem all he would need.
Scam?
volume surge just happened
Not a good sign Pags can't keep the share price up based on substance, he needs shakerzzz to help.
I hope your right, but if I had dime for every time someone has made that claim on this board, i'd be up about 500%.
Is the 25OZ bottle a month supply?
is it take an oz per day like a mulit-vitamin type thing?
Anyone know?
I have seen products like this sell good if that is the case
Hmmmmmmmmmmmmmmm, I wonder what is next move will be
.0008
I would like a slice,
10 baggerzzzzzzzzzzzzzzz, need a 10 baggerzzzzzzzzzzzzzz to break even.
lol, me too, but you paid to much for your shares.
They were not worth .0001 at the time you bought them.
There was no bid
You paid to much for your shares.lol
They???????
Still no buying pressure, mikey's reputation will make sure of that.
This is the problem
Atleast its holding and not tanking, so far
The decimal is in the wrong place.
PUSH
Keep pushing!
I want my money back
11 baggerzzzzzz, I need an 11 baggerzzzzzz to break even,
approx.
Can you post the PR?
I can seem to find it
Well, at least we can go to a whole foods or super target and verify if this product is on the shelves.
dilution, Hopefully it stops soon
my guess is about $100,000 was made from it if it started yesterday morning.
Anyone know of any other explanation?
Hard To Treat Diseases (HTDS) - Large scale integrating project HEALTH 2009
HTDS - IBISS GROUP COMPETED FOR THE EUROPEAN COLLABORATIVE PROJECT - LARGE SCALE INTEGRATING PROJECT HEALTH 2009
BELGRADE, March 17 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS) http://www.htdsmedical.com/ is pleased to announce that the IBISS Group members from Slavica Biochem and part of a large International group of scientists, clinicians, management experts, small enterprises and industry from: Austria, Germany, Israel, Netherlands, Sweden, UK competed for the European Collaborative Project (large integrating project HEALTH 2009). Topics for single-stage submission and evaluation with a deadline of December 3, 2008 were successfully met by the company. Selection will be made sometime in 2009.
More details about the European Collaborative Project can be viewed by visiting these web site links.
http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/c all-for-proposals_en.html
http://ecentres.net/content/events/fp7-health-2009-single-stage_- _deadline_03_december_2008
The Indicative announced budget is EUR 476 million and focused on: BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
Slavica Biochem submission is on the Brain and brain-related diseases; as it relates to treatment of Multiple Sclerosis by means of stem cell therapy.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.
CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at . Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact Andrea Zecevic Hbsc. Msci; via e-mail at .
Andrea Zecevic obtained her degrees at the University of Toronto Canada.
Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief
Liaison Director between the China and Serbia operating subsidiaries. For any
corporate matters, readers should contact the company directly at
Looking at that chart, it seems the best pps is in the morning and goes lower throught the day.
Huge for you maybe, not me.lol
10 baggerzzzzzzzzzzzzzzzzzzzzzz
.0028
She's gunna run.
GO HTDS
if you look at the chart posted by janice in the ibox. She indicated mm's were shorting it at one point.
What if instead of dilution tomorrow, we get mm's caught short and in need to cover.
Maybe that is what the volume today was about.
all just a guess from a novice trader.
HTDS News
Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple SclerosisLast update: 3/16/2009 4:30:00 PMBELGRADE, March 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:
- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug applicationIn 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition. Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks. CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com SOURCE Hard to Treat Diseases
Copyright (C) 2009 PR Newswire. All rights reserved
Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple SclerosisLast update: 3/16/2009 4:30:00 PMBELGRADE, March 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:
- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug applicationIn 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition. Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks. CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com SOURCE Hard to Treat Diseases
Copyright (C) 2009 PR Newswire. All rights reserved
NEWS!!
Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple SclerosisLast update: 3/16/2009 4:30:00 PMBELGRADE, March 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:
- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug applicationIn 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition. Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks. CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com SOURCE Hard to Treat Diseases
Copyright (C) 2009 PR Newswire. All rights reserved
I think the shares are held tight, so if no dilution.
10 bagger in my opinion.